Asymchem Competitors and Similar CompaniesClear all

Asymchem's competitors and similar companies include Genentech, Cipla and Sterling Pharma Solutions.

	Asymchem Asymchem Laboratories (Tianjin) (凯莱英医药集团 (天津) 股份有限公司) is a company engaged in contract research, development, and manufacturing of pharmaceutical products.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Sterling Pharma Solutions Sterling Pharma Solutions is a company providing small molecule API development and manufacturing services.
Founding Date	Founding Date 1999	Founding Date 1976	Founding Date 1935	Founding Date 1969
Type	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma supply chain management	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare contractor drug development pharma supply chain management
Locations	Locations Tianjin, CN HQ Fuxin, CN see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations Dudley, GB HQ Deeside, GB Cary, US Germantown, US Germantown, US
Employees	Employees 9,595	Employees 18,077	Employees 27,764	Employees 9211% increase
Financial
Revenue (est.)	Revenue (est.) ¥6.6b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A
Cost of goods	Cost of goods ¥3.9b (FY, 2025)	Cost of goods N/A	Cost of goods ₹97.2b (FY, 2026)	Cost of goods N/A
Gross profit	Gross profit ¥2.7b (FY, 2025)	Gross profit N/A	Gross profit ₹184.4b (FY, 2026)	Gross profit N/A
Net income	Net income ¥1.1b (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)	Net income N/A